Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 134

Sort by

Sort Order Select

Journal Articles

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Bridget Marcellino, MD PhD, Bruno Cassinat, PharmD, PhD, Noushin Farnoud, PhD, Min Lu, PhD, Emmanuelle Verger, PhD, Erin McGovern, BA, Minal A Patel, MPH, Heidi E. Kosiorek, MS, Meenakshi Mehrotra, PhD, Jane Houldsworth, PhD, Amylou C. Dueck, PhD, Michael Rossi, PhD, Jean-Jacques Kiladjian, MD PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 838.

https://doi.org/10.1182/blood-2019-128342

Published: 2019

Journal Articles

Predictive Values of Early ST2 for Acute Graft-Versus-Host Disease and Transplant-Related Complications after Allogeneic Stem Cell Transplantation

Takuya Miyazaki, Ayako Matsumura, MD, Takayoshi Tachibana, Taiki Ando, MD, Megumi Koyama, MD, Satoshi Koyama, MD, Yoshimi Ishii, MD, Hiroyuki Takahashi, MD, Yuki Nakajima, MD, Ayumi Numata, MD, Wataru Yamamoto, MD, Kenji Motohashi, MD, Maki Hagihara, MD PhD, Kenji Matsumoto, MD, Shin Fujisawa, MD, Hideaki Nakajima, MD

Blood (2019) 134 (Supplement_1): 1976.

https://doi.org/10.1182/blood-2019-123262

Published: 2019

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

https://doi.org/10.1182/blood-2019-125423

Published: 2019

Journal Articles

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Marion Eveillard, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Eric L Smith, MD PhD, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X Lu, MD PhD, Neha Korde, MD, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 4377.

https://doi.org/10.1182/blood-2019-128938

Published: 2019

Journal Articles

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Alexander E. Perl, MD, Naval G. Daver, MD, Keith W. Pratz, MD, Joseph Maly, MD, Wan-Jen Hong, MD, Erkut Bahceci, Bo Tong, PhD, Tian Tian, PhD, Kimberley Dilley, MD MPH

Blood (2019) 134 (Supplement_1): 3910.

https://doi.org/10.1182/blood-2019-127416

Published: 2019

Journal Articles

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Blood (2019) 134 (Supplement_1): 4161.

https://doi.org/10.1182/blood-2019-127923

Published: 2019

Journal Articles

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia-Single Center Retrospective Analysis

Seema Shrinivas Bhatwadekar, MDMDcine, Shubhangi Vishwas Deshpande, MD, Arpan Mehta, MD, Parth Shah, MD

Blood (2019) 134 (Supplement_1): 4162.

https://doi.org/10.1182/blood-2019-126495

Published: 2019

Journal Articles

Noninvasive and Wearable Optical Monitoring of Brain Death with Aid of a Protocol at Differentiated Fractions of Oxygen Inspired

Ting Li, PhD, Pan Boan, Master, Yuan Gao, Master, Huang Xiaobo, Jiangbo Pu, PhD, Chong Huang

Blood (2019) 134 (Supplement_1): 5808.

https://doi.org/10.1182/blood-2019-124448

Published: 2019

Journal Articles

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Mark Acosta, PharmD, Arrash Darban, PharmD, MS, Matthew Gitlin, PharmD

Blood (2019) 134 (Supplement_1): 5869.

https://doi.org/10.1182/blood-2019-124990

Published: 2019

Journal Articles

Healthcare Resource Utilization with Rasburicase in the Management of Patients with Tumor Lysis in the Outpatient Setting: Results from a Community Oncology Cohort

Ali McBride, PharmD,MS, Melissa Hagan, PhD, Mei Xue, MBA, Robert E Smith, MD

Blood (2019) 134 (Supplement_1): 3401.

https://doi.org/10.1182/blood-2019-125922

Published: 2019

Journal Articles

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Daniel Bottomly, Nicola Long, Fei Yang, MD, Tiffany Lee, MD, Uma Borate, MD, Beth Wilmot, PhD, Adam S DuVall, MD, Andrea Monteblanco, BS, Karina Thiel-Klare, Gabby Dewson, BA, Richard D. Press, MD PhD, Cristina E. Tognon, Brian J. Druker, Jeffrey W. Tyner, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2019) 134 (Supplement_1): 1407.

https://doi.org/10.1182/blood-2019-132224

Published: 2019

Journal Articles

Yet do much less...so much less!

Jeffrey H. Lipton

Blood (2019) 134 (1): 6–7.

https://doi.org/10.1182/blood.2019001014

Published: 2019

Journal Articles

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Yehuda E. Deutsch, MD, Justin T Presutto, PharmD, MBA, Amanda Brahim, Pharm.D., Jyotishankar Raychaudhuri, MD, Marco Andres Ruiz, MD, Jose Sandoval-Sus, MD, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2018-99-115682

Published: 2018

Journal Articles

Trends in ADAMTS13 Activity Testing over the Last 7 Years in a Single UK TTP Specialist Centre

Kat Moss, MBBS, MRCP, Colin Downey, Ashley Lawrenson, Tina Dutt, PhD MBBS, BSc, FRCPath, FRCP, Rebecca J Shaw

Blood (2018) 132 (Supplement 1): 3526.

https://doi.org/10.1182/blood-2018-99-119331

Published: 2018

Journal Articles

A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)

Jessica Choudhry, PharmD, RPh, Mandy Parson, BSN, Jacqueline Wright

Blood (2018) 132 (Supplement 1): 5211.

https://doi.org/10.1182/blood-2018-99-117353

Published: 2018

Journal Articles

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

Robert Puckrin, MD, Eshetu G Atenafu, M.Sc., P.Stat, Jaime Claudio, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Mark D. Minden, MD PhD, Andre Schuh, Tracy Murphy, MDFRCP,FRCPath, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Aaron D Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 436.

https://doi.org/10.1182/blood-2018-99-113090

Published: 2018

Journal Articles

Practice Patterns in the Use of MRI/MRA and Chronic Transfusion Therapy for Monitoring and Treatment of Stroke in Pediatric Patients with Sickle Cell Anemia

Alyssa M Schlenz, PhD, Martina Mueller, PhD, Shannon Phillips, PhD RN, Cathy Melvin, PhD MPH, Robert J. Adams, MD MS, Julie Kanter, MD

Blood (2018) 132 (Supplement 1): 4716.

https://doi.org/10.1182/blood-2018-99-116968

Published: 2018

Journal Articles

Psychological, Physical and Functional Importance of Patient Reported Outcomes Among Cancer Outpatients

Shiva Shrotriya, MD MPH, Declan Walsh, MDMSc FACP FRCP, Mukta Sharma, MBBS, Supratik Rayamajhi, MD

Blood (2018) 132 (Supplement 1): 5904.

https://doi.org/10.1182/blood-2018-99-119641

Published: 2018

Journal Articles

Validation of a Sensitive Flow Cytometry Assay to Assess Minimal Residual Disease of Multiple Myeloma Cells in Apheresis Product

Nicholas Jones, Josette William Ragheb, MD PhD, Brian Ngo, David Uyeji, Anselm L. Hii, MD

Blood (2018) 132 (Supplement 1): 5646.

https://doi.org/10.1182/blood-2018-99-119858

Published: 2018

Journal Articles

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Mohit Narang, MD, Rafat Abonour, MD, Brian G. M. Durie, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Shankar Srinivasan, PhD, E. Dawn Flick, MPH. ScD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3156.

https://doi.org/10.1182/blood.V130.Suppl_1.3156.3156

Published: 2017

NARROW

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Predictive Values of Early ST2 for Acute Graft-Versus-Host Disease and Transplant-Related Complications after Allogeneic Stem Cell Transplantation

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia-Single Center Retrospective Analysis

Noninvasive and Wearable Optical Monitoring of Brain Death with Aid of a Protocol at Differentiated Fractions of Oxygen Inspired

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Healthcare Resource Utilization with Rasburicase in the Management of Patients with Tumor Lysis in the Outpatient Setting: Results from a Community Oncology Cohort

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Yet do much less...so much less!

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Trends in ADAMTS13 Activity Testing over the Last 7 Years in a Single UK TTP Specialist Centre

A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

Practice Patterns in the Use of MRI/MRA and Chronic Transfusion Therapy for Monitoring and Treatment of Stroke in Pediatric Patients with Sickle Cell Anemia

Psychological, Physical and Functional Importance of Patient Reported Outcomes Among Cancer Outpatients

Validation of a Sensitive Flow Cytometry Assay to Assess Minimal Residual Disease of Multiple Myeloma Cells in Apheresis Product

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only